The effect of prolonged administration of hydroxyurea on morbidity and mortality in adult patients with sickle cell syndromes: results of a 17-year, single-center trial (LaSHS)

被引:325
作者
Voskaridou, Ersi [1 ]
Christoulas, Dimitrios [2 ]
Bilalis, Antonios [1 ]
Plata, Eleni [1 ]
Varvagiannis, Konstantinos [1 ]
Stamatopoulos, George [3 ]
Sinopoulou, Klio [1 ]
Balassopoulou, Aggeliki [1 ]
Loukopoulos, Dimitris [4 ]
Terpos, Evangelos [2 ]
机构
[1] Laikon Gen Hosp, Thalassemia Ctr, GR-11526 Athens, Greece
[2] Univ Athens, Sch Med, Dept Clin Therapeut, GR-11527 Athens, Greece
[3] G Gennimatas Gen Hosp, Dept Orthoped, Athens, Greece
[4] Acad Athens, Biomed Res Fdn, Hematol Res Lab, Athens, Greece
关键词
FETAL-HEMOGLOBIN; LEG ULCERS; PULMONARY-HYPERTENSION; CELL/BETA-THALASSEMIA; RISK-FACTORS; DISEASE; ANEMIA; EXPERIENCE; ULCERATION; SEVERITY;
D O I
10.1182/blood-2009-05-221333
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The aim of this prospective study was to evaluate the long-term efficacy and safety of hydroxyurea (HU) in patients with sickle cell disease (SCD). Thirty-four patients with sickle cell anemia (hemoglobin S [HbS]/HbS), 131 with HbS/beta(0)-thal, and 165 with HbS/beta(+)-thal participated in this trial. HU was administered to 131 patients, whereas 199 patients were conventionally treated. The median follow-up period was 8 years for HU patients and 5 years for non-HU patients. HU produced a dramatic reduction in the frequency of severe painful crises, transfusion requirements, hospital admissions, and incidence of acute chest syndrome. The probability of 10-year survival was 86% and 65% for HU and non-HU patients, respectively (P = .001), although HU patients had more severe forms of SCD. The 10-year probability of survival for HbS/HbS, HbS/beta (0)-thal, and HbS/IVSI-110 patients was 100%, 87%, and 82%, respectively, for HU patients and 10%, 54%, and 66%, for non-HU patients. The multivariate analysis showed that fetal hemoglobin values at baseline and percentage change of lactate dehydrogenase between baseline and 6 months were independently predicted for survival in the HU group. These results highlight the beneficial effect of HU, which seems to modify the natural history of SCD and raise the issue of expanding its use in all SCD patients. (Blood. 2010; 115: 2354-2363)
引用
收藏
页码:2354 / 2363
页数:10
相关论文
共 37 条
[1]   Sickle cell hepatopathy: Clinical presentation, treatment, and outcome in pediatric and adult patients [J].
Ahn, H ;
Li, CS ;
Wang, WF .
PEDIATRIC BLOOD & CANCER, 2005, 45 (02) :184-190
[2]   Risk factors for osteonecrosis of the femoral head in patients with sickle cell disease [J].
Akinyoola, A. L. ;
Adediran, I. A. ;
Asaleye, C. M. ;
Bolarinwa, A. R. .
INTERNATIONAL ORTHOPAEDICS, 2009, 33 (04) :923-926
[3]   Hydroxyurea and sickle cell anemia: effect on quality of life [J].
Ballas, Samir K. ;
Barton, Franca B. ;
Waclawiw, Myron A. ;
Swerdlow, Paul ;
Eckman, James R. ;
Pegelow, Charles H. ;
Koshy, Mabel ;
Barton, Bruce A. ;
Bonds, Duane R. .
HEALTH AND QUALITY OF LIFE OUTCOMES, 2006, 4 (1)
[4]  
Ballas SK, 1999, BRIT J HAEMATOL, V105, P491, DOI 10.1111/j.1365-2141.1999.01339.x
[5]  
Chaine B, 2001, ARCH DERMATOL, V137, P467
[6]  
CHARACHE S, 1992, BLOOD, V79, P2555
[7]  
Charache S, 1997, SEMIN HEMATOL, V34, P15
[8]   Hydroxyurea and sickle cell anemia - Clinical utility of a myelosuppressive ''switching'' agent [J].
Charache, S ;
Barton, FB ;
Moore, RD ;
Terrin, ML ;
Steinberg, MH ;
Dover, GJ ;
Ballas, SK ;
McMahon, RP ;
Castro, O ;
Orringer, EP ;
Jones, S ;
Strayhorn, D ;
Rosse, W ;
Phillips, G ;
Peace, D ;
JohnsonTelfair, A ;
Milner, P ;
Kutlar, A ;
Tracy, A ;
Allen, GE ;
Moshang, J ;
Steinberg, M ;
Anderson, A ;
Sabahi, V ;
Pegelow, C ;
Temple, D ;
Case, E ;
Harrell, R ;
Embury, S ;
Schmidt, B ;
Koshy, M ;
TalischyZahed, N ;
Dorn, L ;
Pendarvis, G ;
McGee, M ;
Telfer, M ;
Davis, A ;
Finke, H ;
Perlin, E ;
Siteman, J ;
Gascon, P ;
diPaolo, P ;
Gargiulo, S ;
Eckman, J ;
Bailey, JH ;
Platt, A ;
Waller, L ;
Ramirez, G ;
Knors, V ;
Hernandez, S .
MEDICINE, 1996, 75 (06) :300-326
[9]   Hydroxyurea induces fetal hemoglobin by the nitric oxide-dependent activation of soluble guanylyl cyclase [J].
Cokic, VP ;
Smith, RD ;
Beleslin-Cokic, BB ;
Njoroge, JM ;
Miller, JL ;
Gladwin, MT ;
Schechter, AN .
JOURNAL OF CLINICAL INVESTIGATION, 2003, 111 (02) :231-239
[10]   5-AZACYTIDINE STIMULATES FETAL HEMOGLOBIN-SYNTHESIS IN ANEMIC BABOONS [J].
DESIMONE, J ;
HELLER, P ;
HALL, L ;
ZWIERS, D .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA-BIOLOGICAL SCIENCES, 1982, 79 (14) :4428-4431